Frontlight ResearchEarly access
CompletedPhase 1
Alirocumab in Patients with Sepsis
Key facts
- Who runs it
- Jonathan Sevransky
- Where
- Atlanta, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 50 people enrolled
- Started
- 4 Jan 2023
- Ended
- 23 Feb 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Alirocumab
- Placebo
- Record updated
- 24 March 2025
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Suspected or confirmed infection as evidenced by ordering of blood cultures and administration of at least one antimicrobial agent
- Acute respiratory or cardiovascular organ dysfunction attributed to sepsis as evidenced by at least one of the following requirements:; Vasopressor Requirement - Continuous infusion of norepinephrine, epinephrine, vasopressin, dopamine, phenylephrine or other vasopressor agents at any dose for greater than 1 hour and required to maintain a mean arterial pressure ≥ 65 mm Hg despite intravenous crystalloid infusion of at least 1000cc; Respiratory Support Requirement - Acute hypoxemic respiratory failure defined as persistent hypoxemia requiring (1) intubation and mechanical ventilation, or (2) positive pressure ventilation via tight-fitting face mask or (3) high flow nasal cannula ≥ 45 liters per minute (LPM) flow and fraction of inspired oxygen (FiO2) ≥ 0.40
- Anticipated or confirmed intensive care unit (ICU) admission
Who cannot take part
- Requirement of more than 6 liters (L) nasal cannula (NC) if not receiving invasive mechanical ventilation
- Chronic cardiovascular failure requiring home mechanical hemodynamic support or home chemical hemodynamic support
- Known allergy or known contraindication to alirocumab
- Chronic disease/illness that, in the opinion of the site investigator, have an expected lifespan of < 30 days unrelated to current sepsis diagnosis (e.g, stage IV malignancy, neurodegenerative disease, etc.)
- Organ dysfunction present > 24 hours at time randomization
- Limitations of care (defined as refusal of cardiovascular and respiratory support described under inclusion criteria) including "do not intubate" (DNI) status
- Development of sepsis while in the hospital ( i.e not present on admission to hospital)
- Chronic hypoxemia requiring supplemental non-invasive oxygen or home mechanical ventilation
- Pregnancy
- Prisoner or incarceration
- Current participation in another interventional pharmaceutical research study for sepsis
- Inability or unwillingness of subject or legal surrogate/representative to give written informed consent
Where in United States
- Emory University HospitalAtlanta, United States
- Grady Memorial HospitalAtlanta, United States
About the trial
What the trial wants to find out
The purpose of this study is to determine whether the drug alirocumab, which may lower cholesterol, can reduce the amount of inflammation caused by an infection that has caused either low blood pressure or difficulty breathing. Participants will be randomized to receive a single IV infusion of alirocumab or a placebo.
The 2 groups in the trial
- AlirocumabTreatment being tested
Critically ill participants with sepsis leading to cardiovascular and/or respiratory failure who are randomized to receive alirocumab.
- PlaceboPlacebo, for comparison
Critically ill participants with sepsis leading to cardiovascular and/or respiratory failure who are randomized to receive a placebo to match alirocumab.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- PCSK9 and Lipid Metabolism in Sepsis (PALMS) : a Two-center, Phase 1b Randomized, Placebo-controlled, Double-blind, Clinical Trial of Alirocumab in Patients with Sepsis
- Record updated
- 24 March 2025